The use of VEGF-TKIs in R/M RCC has demonstrated vastly varying effectiveness and toxicities even among agents with multiple overlapping targets; for example, axitinib and sorafenib were found to have similar effectiveness, although axitinib has a much more manageable toxicity profile (46). Here, VEGFA is linked to renal cell carcinoma.